Elsevier

Ophthalmology

Volume 113, Issue 6, June 2006, Pages 930-936
Ophthalmology

Original Article
Trabeculectomy with Mitomycin C: Outcomes and Risk Factors for Failure in Phakic Open-Angle Glaucoma

Presented at: Association for Research in Vision and Ophthalmology Annual Meeting, May 2005, Ft. Lauderdale, Florida.
https://doi.org/10.1016/j.ophtha.2006.01.062Get rights and content

Purpose

To evaluate long-term tonometric outcomes of trabeculectomy with adjunctive mitomycin C (MMC) and its efficacy in achieving a range of intraocular pressures (IOP) in phakic patients with open-angle glaucoma.

Methods

Three levels of success were defined by these criteria: (A) IOP ≤18 mmHg and IOP reduction of 20%; (B) IOP ≤15 mmHg and IOP reduction of 25%; and (C) IOP ≤12 and IOP reduction of 30%. Kaplan-Meier survival analyses were used to assess outcomes. Cox’s proportional hazard regression analysis was used to identify risk factors for failure.

Participants

Two hundred twenty-five phakic patients (292 eyes) with open-angle glaucoma, ≥40 years of age at time of trabeculectomy.

Main Outcome Measures

The primary outcome was qualified success rate (with or without medications) according to the defined criteria. Secondary outcomes include IOP level and number of medications at 1 and 3 years after surgery, postoperative complications, and need for further glaucoma surgery.

Results

Mean IOP (±standard deviation) decreased from 18.8 mmHg (±6.1 mmHg) before surgery to 11.3 mmHg (±4.5 mmHg) at 1 year and 11.1 mmHg (±4.2 mmHg) at 3 years (P<0.001 for both). The mean number of medications decreased from 2.8 (±1.0) to 0.4 (±0.7) at 1 year and 0.7 (±1.0) at 3 years (P<0.001 for both). The success rates were 85%, 84%, and 79% at 1 year for criteria A, B, and C, respectively; and 62%, 56%, and 46% for these criteria, respectively, at 3 years. Postoperative laser suture lysis was associated with a higher rate of failure for criteria B and C (P<0.001 for both), the hazard ratio (HR) was 1.7 for criteria B and 2.0 for criteria C. Prior argon laser trabeculoplasty was associated with higher risk of failure for criteria C (HR = 1.6; P = 0.05).

Conclusions

Trabeculectomy with MMC effectively reduces IOP in phakic open-angle glaucoma, but long-term low IOPs are achieved in only half of the cases. Laser suture lysis after trabeculectomy and prior argon laser trabeculoplasty are associated with a higher risk of failure when low IOPs are required.

Section snippets

Patients

This is a retrospective cohort study of patients with open-angle glaucoma who underwent initial trabeculectomy with adjunctive MMC between August, 1997, and December, 2003, at the Glaucoma Division, Jules Stein Eye Institute, University of California Los Angeles. Two hundred twenty-five phakic patients (292 eyes) with primary open-angle, normal-tension, exfoliative, or pigmentary glaucoma who were 40 years of age or older at the time of trabeculectomy were considered for the study. Eyes that

Preoperative and Intraoperative Characteristics

From August, 1997, through December, 2003, a total of 638 trabeculectomies were performed at the Glaucoma Division, Jules Stein Eye Institute, by one of the authors (JC). Two hundred ninety-two phakic eyes were eligible for the study and 346 were excluded. Eighty-nine eyes were pseudophakic at the time of trabeculectomy, and 39 had undergone prior trabeculectomy. Other criteria for exclusion were narrow or closed angle glaucoma, uveitic glaucoma, traumatic glaucoma, aphakia, age younger than 40

Discussion

The adjunctive use of MMC with trabeculectomy more effectively reduces IOP in the short-term than standard trabeculectomy without antimetabolites.21, 22 The success of trabeculectomy often has been defined arbitrarily as a lowering of the IOP to less than 21 mmHg or a reduction of the IOP by a certain percentage. However, contemporary IOPs often are well below the traditional 21-mmHg level. By setting the cutoff IOP for success at 21 mmHg, the success rate of filtering surgery is overestimated.

References (46)

  • T.H. Kupin et al.

    Adjunctive mitomycin C in primary trabeculectomy in phakic eyes

    Am J Ophthalmol

    (1995)
  • L.K. Mao et al.

    Correlation between intraocular pressure control and progressive glaucomatous damage in primary open-angle glaucoma

    Am J Ophthalmol

    (1991)
  • B. Bergea et al.

    Impact of intraocular pressure regulation on visual fields in open-angle glaucoma

    Ophthalmology

    (1999)
  • G. Rebolleda et al.

    Effect of cataract surgery on IOP after trabeculectomy [letter]

    J Cataract Refract Surg

    (2003)
  • K. Hayashi et al.

    Effect of cataract surgery on intraocular pressure control in glaucoma patients

    J Cataract Refract Surg

    (2001)
  • B.J. Shingleton et al.

    Long-term changes in intraocular pressure after clear corneal phacoemulsificationnormal patients versus glaucoma suspect and glaucoma patients

    J Cataract Refract Surg

    (1999)
  • R.L. Stamper et al.

    Hypotonous maculopathy after trabeculectomy with subconjunctival 5-fluorouracil

    Am J Ophthalmol

    (1992)
  • M.B. Shields et al.

    Clinical and histopathologic observations concerning hypotony after trabeculectomy with adjunctive mitomycin C

    Am J Ophthalmol

    (1993)
  • R. Bindlish et al.

    Efficacy and safety of mitomycin-C in primary trabeculectomyfive-year follow-up

    Ophthalmology

    (2002)
  • A. Azuara-Blanco et al.

    Dysfunctional filtering blebs

    Surv Ophthalmol

    (1998)
  • R. Parrish et al.

    “Late endophthalmitis”—filtering surgery time bomb?

    Ophthalmology

    (1996)
  • A.P. Wells et al.

    Cystic bleb formation and related complications in limbus- versus fornix-based conjunctival flaps in pediatric and young adult trabeculectomy with mitomycin C

    Ophthalmology

    (2003)
  • C. Migdal et al.

    Long-term functional outcome after early surgery compared with laser and medicine in open-angle glaucoma

    Ophthalmology

    (1994)
  • Cited by (166)

    View all citing articles on Scopus

    Manuscript no. 2005-630.

    Supported by unrestricted grants from Research to Prevent Blindness Inc., New York, New York; Fight for Sight Inc., New York, New York; and Allergan Inc., Irvine, California.

    View full text